Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by Angion Biomedica Corp
Information provided by (Responsible Party):
Angion Biomedica Corp Identifier:
First received: February 22, 2012
Last updated: July 13, 2012
Last verified: July 2012

The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).

Condition Intervention Phase
Myocardial Infarction
Drug: BB3
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)

Resource links provided by NLM:

Further study details as provided by Angion Biomedica Corp:

Primary Outcome Measures:
  • Evaluation of reduction in infarct size [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    Evaluation of reduction in infarct size between the BB3 and placebo treatment groups at 1 month.

  • Evaluation of the degree of late ventricular remodeling [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Evaluation of the degree of late ventricular remodeling between the BB3 and placebo treatment groups at 6 months, as measured by increase in LV end-diastolic volume index (LVEDVI).

Secondary Outcome Measures:
  • Change in CK-MB and troponin [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Change in BNP levels [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Change in symptoms and clinical signs of CHF [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Change in LVEDVI, LVESVI and LV ejection fraction (EF) after MI assessed by cine MR (SSFP imaging) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • LVEDVI, LVESVI and LVEF after MI assessed by 2D and 3D echocardiography [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Change between initial semi-quantitative regional wall motion score (17 segment model) by Echocardiography [ Time Frame: 1 and 6 months ] [ Designated as safety issue: No ]
  • Change in regional myocardial radial, circumferential and longitudinal strain [ Time Frame: 1 and 6 months ] [ Designated as safety issue: No ]
  • Frequency of MACE [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Frequency of new onset CHF through 6 months [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Number of hospitalizations for CHF through 6 months [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Incidence of complete ST segment resolution 60 ± 30 minutes after last angiogram [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Frequency of AE, SAEs [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Frequency of MACCE [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • All-cause mortality [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Development of ventricular fibrillation or other life-threatening arrhythmia [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Change from baseline eCrCl [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Change in body weight [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 80
Study Start Date: July 2012
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BB3
small molecule mimetic of hepatocyte growth factor/scatter factor
Drug: BB3
Daily intravenous administration of 2 mg/kg BB3 for four (4) days
Placebo Comparator: Placebo
Normal saline
Drug: Placebo
Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.

Detailed Description:

Percutaneous coronary intervention (PCI) has become the mainstay for treatment of ST-segment elevation myocardial infarction (STEMI). Whereas early recanalization undoubtedly salvages myocardial tissue, reperfusion following prolonged ischemia can also exacerbate injury. Infarct size needs to be limited, and the conditions favoring adaptive ventricular healing and remodeling optimized because in patients with acute myocardial infarction (AMI) who do not die of out-of-hospital arrhythmias, long-term prognosis is dependent on the amount of myocardium that is lost, and the outcome of ventricular remodeling. Angion Biomedical Corp. has identified BB3, a small molecule mimetic of hepatocyte growth factor/scatter factor (HGF/SF) whose activity is expected to preserve tissue viability and attenuate dysfunction in the setting of organ injury while obviating the logistical difficulties associated with gene or protein therapy. HGF/SF is a naturally occurring cell survival factor that holds significant therapeutic potential. BB3 has been shown to possess HGF/SF activities, including protection against heart injury following myocardial infarction. This study is designed to evaluate clinical efficacy of BB3 in patients presenting with acute ST segment elevation myocardial infarction (A-STEMI) who undergo PCI.


Ages Eligible for Study:   21 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent
  2. Estimated body weight < 120 kg and BMI < 30
  3. Subject is experiencing clinical symptoms consistent with acute myocardial infarction (AMI)
  4. Fulfills clinical center's criteria for primary PCI
  5. The subject and his/her physician are willing to comply with the requirements of the study and the specified follow-up evaluations.
  6. If female, either surgically sterile or post-menopausal or using acceptable contraception and agree to use effective birth control regimen during the study period. Men must agree to use condoms during the study period. Women of child bearing potential must have a negative urine or serum pregnancy test.
  7. In the opinion of the Investigator, the subject is capable of understanding and complying with the protocol.

Exclusion Criteria:

  1. Pregnant or nursing subjects and those who plan pregnancy in the period up to 6 months following index procedure.
  2. Cardiogenic shock (Killip class 4) or cardiac arrest
  3. History of prior myocardial infarction or pre-existing Q waves on ECG
  4. An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first six months post enrollment;
  5. Any contraindication to undergo MRI imaging.
  6. Subject has active bleeding or a history of bleeding diathesis or coagulopathy (including heparin induced thrombocytopenia), or refusal to receive blood transfusions if necessary;
  7. Subjects presenting with cardiogenic shock or cardiopulmonary resuscitation prior to randomization;
  8. History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke; stroke or transient ischemic attack within the past 6 months, or any permanent residual neurologic defect; known preceding cardiac ventricular arrhythmia
  9. Impaired renal function or on dialysis.
  10. Impaired hepatic function
  11. Currently participating in or has participated in an investigational drug or medical device study within 30 days or 5 half-lives, whichever is longer, prior to enrollment into this study
  12. Have an active malignancy or history of solid, metastatic, or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed
  13. History of positive human immunodeficiency virus (HIV) test
  14. History of rheumatoid arthritis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01539590

United States, Connecticut
Yale University Medical Center Recruiting
New Haven, Connecticut, United States, 06520
Contact: Laurie Thomas    203-737-8320   
Contact: Louise Gambone    203-737-3427   
Principal Investigator: Frank Giordano, MD         
United States, Minnesota
Minneapolis Heart Institute Foundation Recruiting
Minneapolis, Minnesota, United States, 55407-1139
Contact: Susan Jagger, RN, BSN, CCRC    612-863-7065   
Principal Investigator: Jay Traverse, MD         
Sponsors and Collaborators
Angion Biomedica Corp
  More Information

No publications provided

Responsible Party: Angion Biomedica Corp Identifier: NCT01539590     History of Changes
Other Study ID Numbers: 001-10, 5R44HL091699-03
Study First Received: February 22, 2012
Last Updated: July 13, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Angion Biomedica Corp:
hepatocyte growth factor mimetic
hepatocyte growth factor(HGF)
Myocardial Infarction
Acute ST Segment Elevation Myocardial Infarction (STEMI)
Percutaneous Coronary Intervention (PCI)

Additional relevant MeSH terms:
Myocardial Infarction
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Pathologic Processes
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on October 19, 2014